Evozym Biologics and GenScript Form Strategic Collaboration
News Jun 03, 2011
The companies intend to develop next generation proteins and enzymes by combining Evozym Biologics’ innovative enzyme/protein design capabilities with GenScript’s gene synthesis and protein expression capabilities.
“GenScript is a premier CRO and DNA synthesis company,” noted Joseph Grzymski co-founder and President of Evozym. “We are incredibly excited to introduce them to our protein evolution and computational design platforms. We believe our collaboration will allow both companies to leverage strengths and create next generation bio-products efficiently and cost-effectively.”
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE